1415 related articles for article (PubMed ID: 22249257)
21. Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma.
Mahaffey CM; Mahaffey NC; Holland W; Zhang H; Gandara DR; Mack PC; Forman HJ
J Thorac Oncol; 2012 Jan; 7(1):34-9. PubMed ID: 22089114
[TBL] [Abstract][Full Text] [Related]
22. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
[TBL] [Abstract][Full Text] [Related]
23. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
[TBL] [Abstract][Full Text] [Related]
24. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
25. Role of the Keap1-Nrf2 pathway in cancer.
Leinonen HM; Kansanen E; Pölönen P; Heinäniemi M; Levonen AL
Adv Cancer Res; 2014; 122():281-320. PubMed ID: 24974185
[TBL] [Abstract][Full Text] [Related]
26. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.
Singh A; Boldin-Adamsky S; Thimmulappa RK; Rath SK; Ashush H; Coulter J; Blackford A; Goodman SN; Bunz F; Watson WH; Gabrielson E; Feinstein E; Biswal S
Cancer Res; 2008 Oct; 68(19):7975-84. PubMed ID: 18829555
[TBL] [Abstract][Full Text] [Related]
27. Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.
Togashi Y; Hayashi H; Okamoto K; Fumita S; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Nakagawa K; Nishio K
Lung Cancer; 2015 Apr; 88(1):16-23. PubMed ID: 25704955
[TBL] [Abstract][Full Text] [Related]
28. [Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features].
Xiao Y; Zhu X; Gu Y; Chen S; Liang L; Cao B
Zhongguo Fei Ai Za Zhi; 2018 Mar; 21(3):241-250. PubMed ID: 29587953
[TBL] [Abstract][Full Text] [Related]
29. ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
Vartanian S; Lee J; Klijn C; Gnad F; Bagniewska M; Schaefer G; Zhang D; Tan J; Watson SA; Liu L; Chen H; Liang Y; Watanabe C; Cuellar T; Kan D; Hartmaier RJ; Lau T; Costa MR; Martin SE; Merchant M; Haley B; Stokoe D
Cancer Res; 2019 Oct; 79(19):4828-4839. PubMed ID: 31416841
[TBL] [Abstract][Full Text] [Related]
30. Dysregulation of the Keap1-Nrf2 pathway in cancer.
Leinonen HM; Kansanen E; Pölönen P; Heinäniemi M; Levonen AL
Biochem Soc Trans; 2015 Aug; 43(4):645-9. PubMed ID: 26551706
[TBL] [Abstract][Full Text] [Related]
31. Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies.
Hu L; Miao W; Loignon M; Kandouz M; Batist G
Cancer Chemother Pharmacol; 2010 Aug; 66(3):467-74. PubMed ID: 19940992
[TBL] [Abstract][Full Text] [Related]
32. Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3.
Tang J; Guo F; Du Y; Liu X; Qin Q; Liu X; Yin T; Jiang L; Wang Y
Int J Oncol; 2015 May; 46(5):2083-95. PubMed ID: 25695284
[TBL] [Abstract][Full Text] [Related]
33. The P21-activated kinase expression pattern is different in non-small cell lung cancer and affects lung cancer cell sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Liu Y; Wang S; Dong QZ; Jiang GY; Han Y; Wang L; Wang EH
Med Oncol; 2016 Mar; 33(3):22. PubMed ID: 26820570
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-200a controls Nrf2 activation by target Keap1 in hepatic stellate cell proliferation and fibrosis.
Yang JJ; Tao H; Hu W; Liu LP; Shi KH; Deng ZY; Li J
Cell Signal; 2014 Nov; 26(11):2381-9. PubMed ID: 25049078
[TBL] [Abstract][Full Text] [Related]
35. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
36. Cigarette smoke extract induces EGFR-TKI resistance via promoting EGFR signaling pathway and ROS generation in NSCLC cell lines.
Zhang L; Li J; Hu J; Li D; Wang X; Zhang R; Zhang H; Shi M; Chen H
Lung Cancer; 2017 Jul; 109():109-116. PubMed ID: 28577939
[TBL] [Abstract][Full Text] [Related]
37. Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
Moreira-Leite FF; Harrison LR; Mironov A; Roberts RA; Dive C
J Thorac Oncol; 2010 Jun; 5(6):765-77. PubMed ID: 20421816
[TBL] [Abstract][Full Text] [Related]
38. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
Kobayashi S; Shimamura T; Monti S; Steidl U; Hetherington CJ; Lowell AM; Golub T; Meyerson M; Tenen DG; Shapiro GI; Halmos B
Cancer Res; 2006 Dec; 66(23):11389-98. PubMed ID: 17145885
[TBL] [Abstract][Full Text] [Related]
39. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
40. Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells.
Filosto S; Baston DS; Chung S; Becker CR; Goldkorn T
Mol Cancer Ther; 2013 Aug; 12(8):1579-90. PubMed ID: 23686837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
